Li, Weizhong
Wang, Tao http://orcid.org/0000-0002-1015-8819
Rajendrakumar, Arunraj M. http://orcid.org/0000-0003-4290-7682
Acharya, Gyanada
Miao, Zizhen
Varghese, Berin P. http://orcid.org/0000-0002-7819-9086
Yu, Hailiang
Dhakal, Bibek http://orcid.org/0000-0002-4567-9059
LeRoith, Tanya
Karunakaran, Athira
Tuo, Wenbin http://orcid.org/0000-0002-3764-8981
Zhu, Xiaoping http://orcid.org/0000-0002-1672-9504
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI146063, AI130712)
Article History
Received: 12 September 2023
Accepted: 21 October 2023
First Online: 6 November 2023
Competing interests
: X.Z. is listed as an inventor of the patent: US Patent 9,238,683 B2, issued on Jan. 19, 2016, entitled “Efficient Mucosal Vaccination Mediated by the Neonatal Fc Receptor.” X.Z., W.L., and T.W. are listed as inventors on the following patent applications: U.S. Nonprovisional Patent Application No. 20220098242, filed on February 26, 2021, entitled “Compositions and methods for mucosal vaccination against SARS-CoV-2”. U.S. Provisional Application No.: 63/267782, filed on February 8, 2022, “Systems and Methods for FcRn-targeted Nasal Vaccination.” The remaining authors declare no competing interest.